All In Biotech

Free tool

FAERS Monitor: Osenvelt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761404 or its brand name (Osenvelt, Denosumab-Bmwo). Reports on generic versions are filed under their own applications.

Reports

33

Serious

25

76% of reports

Hospitalization

6

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • arthralgia5
  • back pain4
  • chills4
  • diarrhoea4
  • vomiting4
  • abdominal pain upper3
  • death3
  • drug ineffective3
  • fatigue3
  • headache3
  • pain in extremity3
  • peripheral swelling3
  • bone pain2
  • dizziness2
  • dyspepsia2

Reports by year received

View as table
YearReports
20241
20252
202630

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,126 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bone pain221.85.722
chillsSignal421.78.760
dyspepsia213.03.412
peripheral swellingSignal312.44.221
back painSignal411.04.427
abdominal pain upperSignal39.33.215
arthralgiaSignal57.73.423
pain in extremitySignal36.52.29
vomitingSignal45.42.211
diarrhoeaSignal43.91.66
headache33.01.02
dizziness22.60.71
fatigue32.50.81
death32.20.81
drug ineffective31.50.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.